drugset
drugset / Trial / NCT07153965

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT07153965 ↗

Phase 2 Not yet recruiting 47 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, multicenter phase II study to evaluate the safety and efficacy of sac-TMT plus Tagitanlimab in patients with PD-L1-positive locally advanced or metastatic TNBC.

Timeline

Start
2025-09-01
Primary completion
2026-09-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject KL-A167 Unknown 900 mg Intravenous
Subject Sacituzumab Tirumotecan Other / unclassified 5 mg/kg Intravenous

Indications

triple-negative breast carcinoma